Global $15.4 Billion Macular Degeneration Treatment Market, 2032: Modern Dietary Routines and Sedentary Lifestyles Driving the Incidence of Macular Degeneration [Yahoo! Finance]
Bausch Health Companies Inc. (BHC)
Last bausch health companies inc. earnings: 2/19 06:59 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Report by Type, Stage of Disease, Route of Administration, End User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global macular degeneration treatment market has exhibited significant development with a market valuation of US$ 9.4 billion in 2023. Prospects for this sector indicate an anticipated enlargement to US$ 15.4 billion by 2032, advancing at a compound annual growth rate (CAGR) of 5.64% over the forecast period from 2023-2032. Given the enhancing focus on eye health and innovative treatment modalities, the market is set to confront a transformative phase in the coming years. Primary market propulsion is attributed to the rising prevalence of age-associated macular degeneration and the increase in obesity rates worldwide. Modern dietary routines and sedentary lifestyles are augmenting the incidence of macular degeneration, while excessive screen exposure due to reliance on digital devices poses additional risks. Groundbreaking advan
Show less
Read more
Impact Snapshot
Event Time:
BHC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHC alerts
High impacting Bausch Health Companies Inc. news events
Weekly update
A roundup of the hottest topics
BHC
News
- Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 [Yahoo! Finance]Yahoo! Finance
- Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024Accesswire
- Uveitis Treatment Market and Competitive Landscape Report, 2024: Analysis of Growth Opportunities by Drug Class, Disease Type, Distribution Channel, and Region to 2030 [Yahoo! Finance]Yahoo! Finance
- Bausch Health Announces 2024 Annual Meeting of Shareholder ResultsAccesswire
- Bausch Health Companies Inc. (NYSE: BHC) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
BHC
Earnings
- 5/2/24 - Miss
BHC
Sec Filings
- 5/15/24 - Form 8-K
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- BHC's page on the SEC website